Oncology and Hematology - Global Oncology Academy

161-176 of 651

Conquering the Burden & Impacts of PNH
Conquering the Burden & Impacts of PNH
Project Oncology®
Conquering the Burden & Impacts of PNH
Charles Turck, PharmD, BCPS, BCCCP; Hana Safah, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Hana Safah, MD
- Timothy Kubal, MD
Examining Unmet Needs in Paroxysmal Nocturnal Hemoglobinuria
Examining Unmet Needs in Paroxysmal Nocturnal Hemoglobinuria
Project Oncology®
Examining Unmet Needs in Paroxysmal Nocturnal Hemoglobinuria
Brian P. McDonough, MD, FAAFP
- Brian P. McDonough, MD, FAAFP
Managing PNH Patients: Addressing the Unmet Needs
Managing PNH Patients: Addressing the Unmet Needs
Project Oncology®
Managing PNH Patients: Addressing the Unmet Needs
Charles Turck, PharmD, BCPS, BCCCP; Brian Mulherin, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Brian Mulherin, MD
Stories in PNH: Case Experiences from the Clinic
Stories in PNH: Case Experiences from the Clinic
Project Oncology®
Stories in PNH: Case Experiences from the Clinic
Charles Turck, PharmD, BCPS, BCCCP; Timothy Kubal, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Timothy Kubal, MD
Improving PNH Patient Outcomes
Improving PNH Patient Outcomes
Project Oncology®
Improving PNH Patient Outcomes
Charles Turck, PharmD, BCPS, BCCCP; David Dingli, MD, PhD
- Charles Turck, PharmD, BCPS, BCCCP
- David Dingli, MD, PhD
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Heart Matters
Navigating the Vascular Risks of Cancer Therapy: Balancing Cardiac Safety and Tumor Control
Jun-ichi Abe
- Jun-ichi Abe
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Project Oncology®
Evaluating a Lower-Intensity Treatment Regimen in AML: Phase 2 Results from PARADIGM
Ryan Quigley
- Ryan Quigley
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
Project Oncology®
10-Year PORTEC-3 Outcomes: Chemoradiotherapy in High-Risk Endometrial Cancer
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Project Oncology®
Predicting Prognosis in DLBCL: The Role of Immune-Related Gene Signatures
Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Project Oncology®
Refining Risk, Reducing Burden: ENDORISK-2 and Preoperative Stratification in Endometrial Cancer
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
Project Oncology®
Relapsed or Refractory DLBCL: Reviewing the Expanding Treatment Landscape
MinuteCE®
CDH6 in Focus: Advancing Biomarker-Driven Strategies for Platinum-Resistant Ovarian Cancer
Kathleen Moore, MD, MS; Joyce F. Liu, MD, MPH
0.50 credits 5 episodes
- Kathleen Moore, MD, MS
- Joyce F. Liu, MD, MPH
0.50 credits 5 episodes
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
MinuteCE®
Navigating the Therapeutic Landscape of Platinum-Resistant Ovarian Cancer
Joyce F. Liu, MD, MPH
0.50 program credits
- Joyce F. Liu, MD, MPH
0.50 program credits
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
MinuteCE®
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
Joyce F. Liu, MD, MPH; Kathleen Moore, MD, MS
0.50 program credits
- Joyce F. Liu, MD, MPH
- Kathleen Moore, MD, MS
0.50 program credits
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
MinuteCE®
Clinical Evidence: Insights From Early Trials of CDH6-Targeted Therapies
Joyce F. Liu, MD, MPH
0.50 program credits
- Joyce F. Liu, MD, MPH
0.50 program credits
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
MinuteCE®
Safety and Tolerability of CDH6-Directed Antibody-Drug Conjugates
Kathleen Moore, MD, MS
0.50 program credits
- Kathleen Moore, MD, MS
0.50 program credits

Previous
1
2
…
9
10
11
12
13
…
40
41
Next

11/11